$CGEM

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

Cullinan Therapeutics (CGEM) shares rose 6.6% after positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant progression-free survival benefits. This positions zipalertinib as a potential first-line treatment for a specific subset of non-small cell lung cancer patients, supporting planned U.S. regulatory filings. Cullinan Therapeutics has no revenue but holds a high-risk pipeline with potential in oncology and autoimmune diseases.

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i

Taiho Oncology and Cullinan Therapeutics (CGEM) announced that Phase 3 REZILIENT3 trial data for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC will be presented at the 2026 IASLC World Conference. The trial met its primary endpoint of progression-free survival. Zipalertinib is an investigational EGFR inhibitor.

Michaelson Jennifer (Chief Scientific Officer) sold 30,000 shares of Cullinan Therapeutics, Inc. (CGEM) at $20.26 ($0.61M total) on 2026-08-13 under a Rule 10b5-1 trading plan.

Cullinan Therapeutics (CGEM) shares rose on multiple clinical updates. The company initiated a rolling FDA NDA for Zipalertinib in Nov 2025, received FDA acceptance in Apr 2026, and reported REZILIENT3 topline results on Aug 12, 2026. Other pipeline readouts included CLN-049 and CLN-978. Stock was $7.93 on Jun 29, 2025 and about $20.78 premarket Aug 13, 2026.

Cullinan Oncology (CGEM) shares rose about 6.4% pre-open after the company and partners reported REZILIENT3 Phase 3 results for zipalertinib plus platinum chemo in previously untreated EGFR exon 20 insertion NSCLC. The interim analysis met the primary endpoint with improved progression-free survival. The data supports U.S. first-line approval efforts, with up to $130M in milestones under the Cullinan-Taiho deal and a ~$334.5M cash balance.

Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in

Cullinan Therapeutics (NASDAQ:CGEM) shares rose 1.6% after the company reported positive FDA feedback from an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager for acute myeloid leukemia. The FDA discussed a Phase 2 plan, with a potentially registrational Phase 2 study starting in Q3 2026 and an update on dose escalation in Q4 2026.